IP Verse

Ethypharm opposition analysis

COMPANY ANALYSIS

Latest oppositions filed by Ethypharm

Patent Number:
EP3578173
Title:
Dosage Form Containing Oxycodone And Naloxone
Applicant:
EURO-CELTIQUE S.A.
Opposition Date:
Jul 26, 2023
Patent Number:
EP3345602
Title:
Rapamycin Derivative For Treating Advanced Solid Tumours
Applicant:
NOVARTIS AG
Opposition Date:
Jan 6, 2023
Patent Number:
EP3391890
Title:
Posaconazole Intravenous Solution Formulations Stabilized By Substituted Beta-Cyclodextrin
Applicant:
MERCK SHARP & DOHME CORP.
Opposition Date:
May 25, 2022
Patent Number:
EP3342411
Title:
Rapamycin Derivative For Treating Pancreas Cancer
Applicant:
NOVARTIS AG
Opposition Date:
Feb 14, 2020
Patent Number:
EP2962686
Title:
Dosage Form Containing Oxycodone And Naloxone
Applicant:
EURO-CELTIQUE S.A.
Opposition Date:
Jan 9, 2020
Patent Number:
EP3351246
Title:
Rapamycin Derivative For The Treatment Of A Solid Tumor Associated With Deregulated Angiogenesis
Applicant:
NOVARTIS AG
Opposition Date:
Jul 3, 2019
Patent Number:
EP3143995
Title:
A Rapamycin Derivative For Treating Lung Cancer
Applicant:
NOVARTIS AG
Opposition Date:
Jun 12, 2019
Patent Number:
EP2762140
Title:
Treatment Of Solid Brain Tumours With A Rapamycin Derivative
Applicant:
NOVARTIS AG
Opposition Date:
Dec 22, 2017
Patent Number:
EP2425821
Title:
Pharmaceutical Preparation Containing Oxycodone And Naloxone
Applicant:
EURO-CELTIQUE S.A.
Opposition Date:
Nov 7, 2017
Patent Number:
EP2425824
Title:
Pharmaceutical Preparation Containing Oxycodone And Naloxone
Applicant:
EURO-CELTIQUE S.A.
Opposition Date:
Nov 7, 2017

Competitors of Ethypharm

NOVARTIS AG

EURO-CELTIQUE S.A.

NOVARTIS INTERNATIONAL PHARMACEUTICAL AG

Want to track Ethypharm?

Feel free to send us a message here and we will get back to you